 Issue 014 |
|
Quality, safety and reliability
B. Braun
In an increasingly expanding market, pharmaceutical companies are coming to rely on contract services providers, such as B. Braun, which offer expertise, products and services. more... |
| |
|
| |
Dedicated outsourcing specialist
Enestia
There are many reasons why pharmaceutical companies outsource services to contractors, from complementing manufacturing and packaging processes tocreating custom-designed added value for the long-term future. more... |
| |
|
| |
Strategy for growth
Nycomed
The dynamic market for contract manufacturing has seen low-cost countries take on more commoditised processes. Nycomed, a service provider operating in mature markets for many years, has refocused the top end of its market and succeeded through rapid growth. more...
|
|
 Issue 013 |
|
Comprehensive therapy safety
B. Braun
Drugs alone do not cure people with illnesses: a holistic approach to patient health care is required, from medical devices and procedures to drug delivery and personal hygiene. more... |
| |
|
| |
Commitment to excellence
Nycomed
Pharmaceutical contract manufacturing is a highly competitive business currently growing by 12% a year. But there are only a few third-party manufacturers that can offer capacity supported by know-how, quality assurance and the ability to develop a client’s R&D and transform it into a market product. more... |
| |
|
| |
Complete scientific confidence
MPI Research
Contract research organisations provide many services to pharmaceutical companies to improve production processes and help gain competitive advantage. For added value, however, a CRO must prove itself to be more that just a vendor. more... |
|
 Issue 012 |
|
Expansion rewards for all
Grupo Uriach Integral Contract Services
With new facilities and individually tailored customer care plans, one Spanish contract manufacturer now offers an improved service range. more... |
| |
|
| |
Rules of attraction
Hameln Pharmaceuticals
Dr Dieter Gothier, managing director of Hameln Pharmaceuticals, explains to Lorrie Kelly how the company’s ethos of flexibility, reliability and responsiveness, combined with its new production facility, will ensure strong customer allegiance. more... |
|
 Issue 011 |
|
Effective process chemistry partnering
ROW2 Technologies
During early development of an NCE, process chemists are charged with finding a commercially viable route within a time-constrained environment. Following commercialisation, these scientists move on to the next blockbuster and justifiably little attention is devoted to evaluating alternative syntheses that can cut manufacturing costs. But, through its flagship service RouteDesign, ROW2 Technologies Inc believes an invaluable service for process chemists during route selection is at hand. more... |
| |
|
| |
Search for added value
hameln pharmaceuticals
To find the right contract manufacturer to make high-quality products, service providers need to be evaluated according to an objective catalogue of criteria, and against subjective factors. Product quality and low price were always the decisive factors in selecting a service provider to deal with the contract manufacture of pharmaceuticals. more... |
| |
|
| |
Escape cost and hassle
Cenexi
As a production line ages, it becomes incapable of delivering products that meet current regulatory requirements. However, it is difficult for many pharmaceutical companies to justify the huge investment needed to upgrade or replace it. Outsourcing the production of injectable ampoules to a specialist contractor is one of the most efficient and cost-effective solutions. more... |
| |
|
| |
Partnerships for innovation
Evotec AG
The pharmaceutical industry faces a stiff challenge in revitalising the process of drug discovery, which is perceived to be increasingly under threat. Blockbuster drugs are coming off patent, investment in early-stage biotechnology research is diminishing and the pipeline of new pharmaceutical products needs to be rapidly refilled. Many pharma and biotech companies are now looking to develop partnerships to address these problems, and the signs are that they are achieving a measure of success. more... |
| |
|
| |
Next generation pharma solution
NextPharma
Contract manufacturing has become an essential strategy for pharmaceutical laboratories. Through a number of acquisitions, one European company has broadened its portfolio of services to provide a one-stop shop for the needs of laboratories worldwide. more... |
|
 Issue 010 |
|
Meeting the needs of global clinical trials
Quest Diagnostics
Quest Diagnostics is a leading clinical diagnostic testing company with over 42,000 employees and approximately $6bn in yearly revenues. The clinical trials business within Quest Diagnostics consists of over 500 dedicated employees providing central laboratory testing to support global Phase II–IV clinical trials. more... |
| |
|
| |
Delivering Therapeutic Foresight And Results
INC Research
With a long-standing history of therapeutic speciality and technological innovation, one company has transformed itself from a start-up contract research organisation into a drug development leader specialising in oncology, CNS and paediatrics, with full data services capabilities. more... |
| |
|
| |
The art of organic synthensis
Syncom BV
Despite the pace of technology, the human touch is necessary when it comes to specialist areas. Organic synthesis is a complex field requiring expert knowledge and the experience to know what will work. more... |
| |
|
| |
Taiwan's centre of innovation
The Development Center for Biotechnology (DCB)
The Development Center for Biotechnology has done much to support its country’s biotech industry. The organisation has recently stepped up its activities to act as a bridge to the international community. more... |
| |
|
| |
Outsourcing production reduces costs
Cenexi
With drug producers under great pressure to reduce prices, one contract manufacturer argues that the industry should consider contracting out at least some of its production. more... |
| |
|
| |
The challenges and benefits of biomarkers
BioProof AG
The development costs for new drugs are rapidly and constantly increasing. Since most pharmaceutical companies are already pushing timelines as hard as possible, it is not possible to reduce costs by shortening the non-clinical and clinical programmes. more... |
|
 Issue 009 |
|
Evaluating ozonolysis
KNC Laboratories Co Ltd
Sota Kurita of KNC Laboratories Co Ltd explores the pros and cons of using ozonolysis in pharmaceutical process development. more... |
| |
|
| |
The biomedical heart of Scandinavia
Business Region Göteborg
Göteborg, Scandinavia’s most expansive pharma cluster, offers space for institutions, organisations and businesses with ties to biomedical research and development. more... |
| |
|
| |
PMBs at the crossroads
Medicago, Inc
After several early problems, plant-made biopharmaceuticals are once again attracting attention. Technologies developed by a new generation of biotech companies could help the market achieve commercial maturity, writes Frédéric Ors. more... |
| |
|
| |
Clinical testing and bioanalytical services
Mitsubishi Kagaku Bio-Clinical Laboratories
Established in 1988, Mitsubishi Kagaku Bio-Clinical Laboratories (MBC) has nearly 20 years’ experience of clinical testing and drug development supporting services in Japan. more... |
|
 Issue 008 |
|
Related articles from this issue |
| |
|
| |
 The emergence of virtual screening
High throughput screening of large collections of chemical compounds remains an important step in many drug discovery research projects. Jin Li and Timothy Lovell, Chemical Computing, AstraZeneca, review the complementary virtual screening methodologies. |
| |
|
| |
Is there a mux up?
Nicholas Westwood, University of St
Andrews, and Graham Smith, Pfizer Global
R&D, discuss the technology associated
with the analysis of crude reaction mixtures. more.. |
|
 Issue 007 |
|
Targeting peptides
Karyon Ltd
Karyon Ltd’s operations focus on the discovery, IP protection and early development of carrier peptides that target specific tissues... more.. |
| |
|
| |
Biotechnology partnerships
BioTie Therapies
Biotie Therapies is a drug development biotechnology company with a focus on dependence disorders, inflammatory diseases and thrombosis...
click here for more |
| |
|
| |
The growing pull of peptides
Peptisyntha SA
Demand for peptide APIs is now centred on large quantities of custom-made and complex peptides, and specialist producers are seeing a window of opportunity... more.. |
